Hyderabad-based pharmaceutical company Biological E landed approval from WHO to be an additional manufacturing site for the Johnson & Johnson Covid-19 vaccine.
The US embassy in India congratulated the pharmaceutical company for the same via Twitter, worded, “Congratulations to @biological_e on its @WHO approval as an additional manufacturing site for the Janssen/Johnson & Johnson COVID-19 vaccine! Great progress for the Quad Vaccine and #USIndiaHealth partnerships through U.S. technical support and @DFCgov financing.”
In response to this, Biological E. Limited's managing director, Mahima Datla, said, "We are very happy with this approval, which will address the need for Covid-19 booster doses in India. We have crossed yet another milestone in our Covid-19 vaccination journey. This approval reflects once again the sustained world-class safety standards and high immunogenicity of Corbevax."
A statement issued by the company earlier on June 4 stated that its Corbevax Covid-19 vaccine has been approved by DCGI after a detailed evaluation and deliberations with the Subject Experts Committee for administering the vaccine as a heterologous booster dose to people who have already taken two doses of either Covishield or Covaxin.
The statement also highlighted the fact that the BE’s Corbevax is the first such vaccine in India to be approved as a heterologous Covid-19 booster.
“Biological E's clinical trial data demonstrated that the Corbevax booster dose significantly improved immune response while maintaining the high level of safety required for an effective booster,” the statement read.